Anti-CMA1/ CYM/ CYH functional antibody
Anti-CMA1/ CYM/ CYH functional antibody for cell culture, ELISA & in-vivo assay
Go to CYM/CMA1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T05114-Ab-1/ GM-Tg-hg-T05114-Ab-2 | Anti-Human CYM/CMA1 monoclonal antibody | Human |
GM-Tg-rg-T05114-Ab-1/ GM-Tg-rg-T05114-Ab-2 | Anti-Rat CYM/CMA1 monoclonal antibody | Rat |
GM-Tg-mg-T05114-Ab-1/ GM-Tg-mg-T05114-Ab-2 | Anti-Mouse CYM/CMA1 monoclonal antibody | Mouse |
GM-Tg-cynog-T05114-Ab-1/ GM-Tg-cynog-T05114-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYM/CMA1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T05114-Ab-1/ GM-Tg-felg-T05114-Ab-2 | Anti-Feline CYM/CMA1 monoclonal antibody | Feline |
GM-Tg-cang-T05114-Ab-1/ GM-Tg-cang-T05114-Ab-2 | Anti-Canine CYM/CMA1 monoclonal antibody | Canine |
GM-Tg-bovg-T05114-Ab-1/ GM-Tg-bovg-T05114-Ab-2 | Anti-Bovine CYM/CMA1 monoclonal antibody | Bovine |
GM-Tg-equg-T05114-Ab-1/ GM-Tg-equg-T05114-Ab-2 | Anti-Equine CYM/CMA1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T05114-Ab-1/ GM-Tg-hg-T05114-Ab-2; GM-Tg-rg-T05114-Ab-1/ GM-Tg-rg-T05114-Ab-2; GM-Tg-mg-T05114-Ab-1/ GM-Tg-mg-T05114-Ab-2; GM-Tg-cynog-T05114-Ab-1/ GM-Tg-cynog-T05114-Ab-2; GM-Tg-felg-T05114-Ab-1/ GM-Tg-felg-T05114-Ab-2; GM-Tg-cang-T05114-Ab-1/ GM-Tg-cang-T05114-Ab-2; GM-Tg-bovg-T05114-Ab-1/ GM-Tg-bovg-T05114-Ab-2; GM-Tg-equg-T05114-Ab-1/ GM-Tg-equg-T05114-Ab-2 |
Products Name | Anti-CYM/CMA1 monoclonal antibody |
Format | mab |
Target Name | CYM |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CYM benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T05114-Ag-1 | Recombinant multi-species CMA1/ CYM/ CYH protein |
ORF Viral Vector | pGMLP003483 | human CMA1 Lentivirus plasmid |
ORF Viral Vector | vGMLP003483 | human CMA1 Lentivirus particle |
ORF Viral Vector | pGMLPm001242 | mouse Cma1 Lentivirus plasmid |
ORF Viral Vector | vGMLPm001242 | mouse Cma1 Lentivirus particle |
Target information
Target ID | GM-T05114 |
Target Name | CYM |
Gene ID | 1215,17228,716395,490628,101084796 |
Gene Symbol and Synonyms | chymase,CMA1,CYH,Mcp-5,Mcp5,Mcpt5,MCT1,MMCP-5 |
Uniprot Accession | P23946,P21842 |
Uniprot Entry Name | CMA1_HUMAN,CMA1_CANLF |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000092009 |
Target Classification | N/A |
The target: CYM, gene name: CMA1, also named as CYH, MCT1, chymase. This gene encodes a chymotryptic serine proteinase that belongs to the peptidase family S1. It is expressed in mast cells and is thought to function in the degradation of the extracellular matrix, the regulation of submucosal gland secretion, and the generation of vasoactive peptides. In the heart and blood vessels, this protein, rather than angiotensin converting enzyme, is largely responsible for converting angiotensin I to the vasoactive peptide angiotensin II. Alternative splicing results in multiple variants. [provided by RefSeq, Apr 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.